Metraipolis › archive › dc_b030cc1a1fca

Alternative 5-Azacitidine 5-Day 100 mg/m2 Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic… — Europe PMC PMID:41311530

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41311530
DOI
10.1002/jha2.70185
License (as archived)
solo-consultazione
Archived
2026-11-08T06:08:08.715Z
SHA-256 of the archived text
d8aa0d22a2d2ab3c21d1ee2aaec11b822e8e68d790cf7f39506ae9a8a2d98365
Stable URL of this page
https://metraipolis.com/documento/dc_b030cc1a1fca

How to cite

Alternative 5-Azacitidine 5-Day 100 mg/m2 Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic… — Europe PMC PMID:41311530 — Europe PMC (en), https://europepmc.org/article/MED/41311530 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b030cc1a1fca (Metraipolis archive dc_b030cc1a1fca, sha256 d8aa0d22a2d2ab3c21d1ee2aaec11b822e8e68d790cf7f39506ae9a8a2d98365)
BibTeX
@misc{dcb030cc1a1fca,
  title = {Alternative 5-Azacitidine 5-Day 100 mg/m2 Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic… — Europe PMC PMID:41311530},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41311530},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b030cc1a1fca; sha256 d8aa0d22a2d2ab3c21d1ee2aaec11b822e8e68d790cf7f39506ae9a8a2d98365},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41311530. Agents can read the archived copy with the MCP tool read_document.